Compare USAS & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USAS | AMRX |
|---|---|---|
| Founded | 1998 | 2002 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.7B |
| IPO Year | 2004 | 2018 |
| Metric | USAS | AMRX |
|---|---|---|
| Price | $6.09 | $13.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $6.50 | ★ $15.60 |
| AVG Volume (30 Days) | ★ 5.3M | 1.2M |
| Earning Date | 05-08-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 157.89 |
| EPS | N/A | ★ 0.22 |
| Revenue | N/A | N/A |
| Revenue This Year | $174.68 | $4.48 |
| Revenue Next Year | $53.17 | $7.13 |
| P/E Ratio | ★ N/A | $60.02 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.55 | $7.02 |
| 52 Week High | $10.50 | $15.42 |
| Indicator | USAS | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.48 | 51.49 |
| Support Level | $4.71 | $12.50 |
| Resistance Level | $6.24 | $13.54 |
| Average True Range (ATR) | 0.42 | 0.41 |
| MACD | 0.17 | 0.13 |
| Stochastic Oscillator | 47.07 | 50.26 |
Americas Gold And Silver Corp is a mining company engaged in the acquisition, exploration, development, and production of precious metals mineral properties in Mexico and the United States. The company's primary operating assets, which are also its reporting segments, are the Cosala operations, the Galena Complex, and Relief Canyon. It also holds interests in the San Felipe Development Project located in Sonora, Mexico. The Cosala operations segment, which derives maximum revenue, operates in Mexico, while the Galena Complex and Relief Canyon segments operate in the United States.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.